Skip to main content
Top
Published in: Diabetologia 8/2010

01-08-2010 | Article

Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction—a nationwide study

Authors: M. L. Norgaard, S. S. Andersen, T. K. Schramm, F. Folke, C. H. Jørgensen, M. L. Hansen, C. Andersson, D. M. Bretler, A. Vaag, L. Køber, C. Torp-Pedersen, G. H. Gislason

Published in: Diabetologia | Issue 8/2010

Login to get access

Abstract

Aims/hypothesis

We assessed secular trends of cardiovascular outcomes following first diagnosis of myocardial infarction (MI) or diabetes in an unselected population.

Methods

All Danish residents aged ≥30 years without prior diabetes or MI were identified by individual-level linkage of nationwide registers. Individuals hospitalised with MI or claiming a first-time prescription for a glucose-lowering medication (GLM) during the period from 1997 to 2006 were included. Analyses were by Poisson regression models. Primary endpoints were death by all causes, cardiovascular death and MI.

Results

The study included 3,092,580 individuals, of whom 77,147 had incident MI and 118,247 new-onset diabetes. MI patients had an increased short-term risk of all endpoints compared with the general population. The rate ratio (RR) for cardiovascular death within the first year after MI was 11.1 (95% CI 10.8–11.5) in men and 14.8 (14.3–15.3) in women, respectively. The risk rapidly declined and 1 year after the index MI, RR was 2.11 (2.00–2.23) and 2.8 (2.64–2.97) in men and women, respectively. Patients with diabetes carried a constantly elevated risk of all endpoints compared with the general population. The cardiovascular death RR was 1.90 (1.77–2.04) and 1.92 (1.78–2.07) in men and women, respectively during the first year after GLM initiation.

Conclusions/interpretation

Incident MI is associated with high short-term risk, which decreases rapidly over time. Incident diabetes is associated with a persistent excessive cardiovascular risk after initiation of GLM therapy. This further strengthens the necessity of early multi-factorial intervention in diabetes patients for long-term benefit.
Literature
1.
go back to reference Schramm TK, Gislason GH, Kober L et al (2008) Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 117:1945–1954CrossRefPubMed Schramm TK, Gislason GH, Kober L et al (2008) Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 117:1945–1954CrossRefPubMed
2.
go back to reference Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234CrossRefPubMed Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234CrossRefPubMed
3.
go back to reference Dale AC, Vatten LJ, Nilsen TI, Midthjell K, Wiseth R (2008) Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. BMJ 337:a236CrossRefPubMed Dale AC, Vatten LJ, Nilsen TI, Midthjell K, Wiseth R (2008) Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. BMJ 337:a236CrossRefPubMed
4.
go back to reference Booth GL, Kapral MK, Fung K, Tu JV (2006) Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 368:29–36CrossRefPubMed Booth GL, Kapral MK, Fung K, Tu JV (2006) Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 368:29–36CrossRefPubMed
5.
go back to reference Preis SR, Hwang SJ, Coady S et al (2009) Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 119:1728–1735CrossRefPubMed Preis SR, Hwang SJ, Coady S et al (2009) Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 119:1728–1735CrossRefPubMed
6.
go back to reference Thomas RJ, Palumbo PJ, Melton LJ 3rd et al (2003) Trends in the mortality burden associated with diabetes mellitus: a population-based study in Rochester, Minn, 1970–1994. Arch Intern Med 163:445–451CrossRefPubMed Thomas RJ, Palumbo PJ, Melton LJ 3rd et al (2003) Trends in the mortality burden associated with diabetes mellitus: a population-based study in Rochester, Minn, 1970–1994. Arch Intern Med 163:445–451CrossRefPubMed
8.
go back to reference Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46:263–268PubMed Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46:263–268PubMed
9.
go back to reference Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M (2003) The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 56:124–130CrossRefPubMed Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M (2003) The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 56:124–130CrossRefPubMed
10.
go back to reference Andersen HR, Nielsen TT, Rasmussen K et al (2003) A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349:733–742CrossRefPubMed Andersen HR, Nielsen TT, Rasmussen K et al (2003) A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349:733–742CrossRefPubMed
11.
go back to reference Gislason GH, Abildstrom SZ, Rasmussen JN et al (2005) Nationwide trends in the prescription of beta-blockers and angiotensin-converting enzyme inhibitors after myocardial infarction in Denmark, 1995–2002. Scand Cardiovasc J 39:42–49CrossRefPubMed Gislason GH, Abildstrom SZ, Rasmussen JN et al (2005) Nationwide trends in the prescription of beta-blockers and angiotensin-converting enzyme inhibitors after myocardial infarction in Denmark, 1995–2002. Scand Cardiovasc J 39:42–49CrossRefPubMed
12.
go back to reference Rasmussen JN, Gislason GH, Abildstrom SZ et al (2005) Statin use after acute myocardial infarction: a nationwide study in Denmark. Br J Clin Pharmacol 60:150–158CrossRefPubMed Rasmussen JN, Gislason GH, Abildstrom SZ et al (2005) Statin use after acute myocardial infarction: a nationwide study in Denmark. Br J Clin Pharmacol 60:150–158CrossRefPubMed
13.
go back to reference Kontny F (2001) Improving outcomes in acute coronary syndromes—the FRISC II trial. Clin Cardiol 24:I3–I7CrossRefPubMed Kontny F (2001) Improving outcomes in acute coronary syndromes—the FRISC II trial. Clin Cardiol 24:I3–I7CrossRefPubMed
14.
go back to reference Fox KA, Mehta SR, Peters R et al (2004) Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) Trial. Circulation 110:1202–1208CrossRefPubMed Fox KA, Mehta SR, Peters R et al (2004) Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) Trial. Circulation 110:1202–1208CrossRefPubMed
15.
go back to reference Gislason GH, Rasmussen JN, Abildstrom SZ et al (2006) Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 27:1153–1158CrossRefPubMed Gislason GH, Rasmussen JN, Abildstrom SZ et al (2006) Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 27:1153–1158CrossRefPubMed
16.
go back to reference Lee HY, Cooke CE, Robertson TA (2008) Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 14:271–280PubMed Lee HY, Cooke CE, Robertson TA (2008) Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 14:271–280PubMed
17.
go back to reference Malacrida R, Genoni M, Maggioni AP et al (1998) A comparison of the early outcome of acute myocardial infarction in women and men. The Third International Study of Infarct Survival Collaborative Group. New Engl J Med 338:8–14CrossRefPubMed Malacrida R, Genoni M, Maggioni AP et al (1998) A comparison of the early outcome of acute myocardial infarction in women and men. The Third International Study of Infarct Survival Collaborative Group. New Engl J Med 338:8–14CrossRefPubMed
18.
go back to reference Dominguez H, Schramm TK, Norgaard ML et al (2009) Initiation and persistence to statin treatment in patients with diabetes receiving glucose-lowering medications 1997–2006. Open Cardiovasc Med J 3:152–159CrossRefPubMed Dominguez H, Schramm TK, Norgaard ML et al (2009) Initiation and persistence to statin treatment in patients with diabetes receiving glucose-lowering medications 1997–2006. Open Cardiovasc Med J 3:152–159CrossRefPubMed
19.
go back to reference Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005–2012CrossRefPubMed Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005–2012CrossRefPubMed
20.
go back to reference Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589CrossRefPubMed Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589CrossRefPubMed
21.
go back to reference Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393CrossRefPubMed Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393CrossRefPubMed
22.
go back to reference Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591CrossRefPubMed Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591CrossRefPubMed
23.
go back to reference Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559CrossRefPubMed Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559CrossRefPubMed
24.
go back to reference Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139CrossRefPubMed Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139CrossRefPubMed
25.
go back to reference Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRefPubMed Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRefPubMed
26.
go back to reference Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T (2007) Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 28:150–154CrossRefPubMed Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T (2007) Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 28:150–154CrossRefPubMed
27.
go back to reference Gaist D, Sorensen HT, Hallas J (1997) The Danish prescription registries. Dan Med Bull 44:445–448PubMed Gaist D, Sorensen HT, Hallas J (1997) The Danish prescription registries. Dan Med Bull 44:445–448PubMed
28.
go back to reference Fox CS, Sullivan L, D'Agostino RB Sr, Wilson PW (2004) The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diab Care 27:704–708CrossRef Fox CS, Sullivan L, D'Agostino RB Sr, Wilson PW (2004) The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diab Care 27:704–708CrossRef
29.
go back to reference Harris MI, Klein R, Welborn TA, Knuiman MW (1992) Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diab Care 15:815–819CrossRef Harris MI, Klein R, Welborn TA, Knuiman MW (1992) Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diab Care 15:815–819CrossRef
30.
go back to reference Howard BV, Best LG, Galloway JM et al (2006) Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diab Care 29:391–397CrossRef Howard BV, Best LG, Galloway JM et al (2006) Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diab Care 29:391–397CrossRef
31.
go back to reference Scognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A (2006) Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 47:65–71CrossRefPubMed Scognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A (2006) Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 47:65–71CrossRefPubMed
32.
go back to reference Labarere J, Stone RA, Obrosky DS et al (2007) Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: a propensity-adjusted analysis. Chest 131:480–488CrossRefPubMed Labarere J, Stone RA, Obrosky DS et al (2007) Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: a propensity-adjusted analysis. Chest 131:480–488CrossRefPubMed
33.
go back to reference American Diabetes Association (2008) Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31:596–615CrossRef American Diabetes Association (2008) Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31:596–615CrossRef
34.
go back to reference Abildstrom SZ, Rasmussen S, Madsen M (2005) Changes in hospitalization rate and mortality after acute myocardial infarction in Denmark after diagnostic criteria and methods changed. Eur Heart J 26:990–995CrossRefPubMed Abildstrom SZ, Rasmussen S, Madsen M (2005) Changes in hospitalization rate and mortality after acute myocardial infarction in Denmark after diagnostic criteria and methods changed. Eur Heart J 26:990–995CrossRefPubMed
Metadata
Title
Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction—a nationwide study
Authors
M. L. Norgaard
S. S. Andersen
T. K. Schramm
F. Folke
C. H. Jørgensen
M. L. Hansen
C. Andersson
D. M. Bretler
A. Vaag
L. Køber
C. Torp-Pedersen
G. H. Gislason
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1783-z

Other articles of this Issue 8/2010

Diabetologia 8/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.